Neuropsychiatric Research Center of Southwest Florida

The majority of Americans are very aware of the mounting statistics concerning the morbidity and mortality of Alzheimer's disease. Currently, 5.2 million Americans, 500,000 Floridians and approximately 25-40,000 Southwest Florida residents are affected by this disease that is yet to be cured or treated and robs individuals from having a productive and meaningful life. Alzheimer's disease is the 6th leading cause of death in the United States, with 40 new cases diagnosed every hour, 980 per day and 360,000 per year. Palliative treatment which has no effect on the progression or outcome will cost over 200 billion dollars this year alone. We know that this disease starts to change the brain up to twenty years before the first symptoms appear. Age is the biggest risk factor, with 10% of those 65 years of age affected and 50% affected by the age of 85.The only mechanism our society has historically and successfully utilized to treat, eradicate or stabilize disease is the development of medications, vaccinations or interventions made possible by patient participation in clinical trials. Double blind placebo controlled clinical trials have been responsible for the development of every FDA approved medication on the market over the past 40 years. There is currently no cure or effective treatment available to impact the progression and decline of Alzheimer's disease and the data from many well run trials has been disappointing, however, on the positive side, we are at a pivotal time medically and scientifically. We now have diagnostic imaging advances, increased understanding of the molecular and genetic mechanisms causing this disease, and the identification of several biomarkers that have the ability to identify probable progression to Alzheimer's disease years before any symptoms. In addition, the continued efforts of the private and public sector to identify and screen potential compounds, as well as other medical procedures, in order to place them into pivotal clinical trials.The Neuropsychiatric Research Center of Southwest Florida has been identified as a research organization that has not only participated in over 100 clinical trials for memory related issues, but also is seen as the key destination for the placement of pharmaceutical trials in Southwest Florida. Currently, the center has 8 enrolling studies in all phases of memory loss, utilizing cutting edge technologies such as PET scans, MRI scans, genetic testing and monoclonal antibody treatments to name a few. These trials are carried out by a skilled medical research team and all costs are covered by the pharmaceutical sponsor. If you or a loved one has concerns regarding the development of Alzheimer's disease or other cognitive issues, please consider calling the Neuropsychiatric Research Center, 939-7777, for a free memory screening.The quest for a cure depends on patients and their loved ones participating in clinical research. Michael J. FoxEditors Note: This article was submitted by Frederick W. Schaerf, M.D., Ph.D. Neuropsychiatric Associates and Neuropsychiatric Research Center of Southwest Florida

Within the next 40 years, the number of those in the United States diagnosed with Alzheimers Disease will jump from five million to an estimated 13 million. It is hoped that treatments currently being developed and tested by pharmaceutical companies will ultimately change the course and symptomatic progression of this debilitating disorder. Of particular interest are treatments aimed at slowing or stopping the progression of cognitive decline rather than maximizing existing cognitive functions, as other treatments do.Before the Food and Drug Administration (FDA) approves any prescription or over-the-counter medication, it subjects the pharmaceutical to rigorous clinical trials. These double-blind, placebo-controlled, randomized studies are performed at research centers throughout the country, allowing those with Alzheimers Disease and other disorders to obtain new and potentially efficacious treatments before they are generally available.Through Neuropsychiatric Research Center of Southwest Florida, numerous Southwest Florida residents have participated in clinical research trials of pharmaceutical treatments that are now FDA-approved, including Namenda, Aricept and more.What trials are currently enrolling and who can participate?Enrollment for clinical research trials is guided by diagnostic and other criteria. Each FDA-regulated trial is closely monitored by an independent institutional review board, with the safety and privacy of each subject paramount. Among currently enrolling trials are those seeking subjects who have been diagnosed with mild to moderate and moderate to severe Alzheimers Disease. This article was submitted by By Frederick W. Schaerf, M.D., Ph.D. Principalinvestigator, Neuropsychiatric Research Center of Southwest Center. He can be reached at 239-939-7777.